Abstract：Objective: To observe the effect of ticagrelor combined with aspirin on platelet function in elderly patients with acute myocardial infarction (AMI).Methods: 200 patients with acute myocardial infarction treated in our hospital from January 2015 to December 2016 were randomly divided into clopidogrel group (101 cases),ticagrelor group (99 cases),and clopidogrel group Loaded aspirin 300mg+ clopidogrel 600mg,the next day was changed to maintenance dose aspirin 100mg/d and clopidogrel 75mg/d;the ticagrelor group was given aspirin 300mg + ticagrelor 180mg,changed to the maintenance dose the next day Aspirin 100mg/d and ticagrelor180mg/d were tested for platelet reaction index (PRI) before and 1,6 and 12 months after administration,and the main adverse cardiovascular events (MACCE) and myocardial infarction thrombolytic therapy were observed ( TIMI) bleeding event.Results: 99 patients in the clopidogrel group completed the follow-up,99 patients in the ticagrelor group completed the follow-up,5 patients in the clopidogrel group were aspirin intolerant,replaced with cilostazol,and 6 patients in the ticagrelor In the Luo group,aspirin intolerance was replaced by cilostazol.The patients in the two groups insisted on taking the drug,and no drug withdrawal due to allergy occurred.After receiving clopidogrel and ticagrelor patients,the difference in PRI was statistically significant (F = 13.169,P<0.001).Before treatment,1 month,6 months,and 12 months,The PRI differences were statistically significant (F = 21.574,P<0.001),and there were interactions between different groups and time.The differences between the two groups at the same time point were statistically significant (all P<0.001),different times within the same group between points,the trend of decreasing PRI (all P<0.001).The two groups of patients were followed up.After one year of treatment,MACCE occurred in 4% of patients in the ticagrelor group and in 13% of patients in the clopidogrel group.The difference between the two groups was statistically significant (P=0.01).During 1 year of follow-up,there was no statistically significant difference in the incidence of TIMI bleeding between the two groups,and ticagrelor did not increase the risk of bleeding.Conclusion: Patients with ticagrelor AMI can further reduce the MACCE event without increasing the risk of bleeding.
陈永旭, 李伟维. 替格瑞洛对老年急性心肌梗死患者血小板功能的影响及其临床疗效[J]. 河北医学, 2020, 26(11): 1846-1850.
CHEN Yongxu, LI Weiwei. Effect of Ticagrelor on Platelet Function in Elderly Patients with AMI and Its Clinical Efficacy. HeBei Med, 2020, 26(11): 1846-1850.
[1] Yan Y,Xiao W,Fan JY,et al.Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes inpatients with acute coronary syndrome:[J].Journal of Geriatric Cardiology,2016,13(3):209~217. [2] 贾亮亮,柯永胜.急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J].中国临床药理学与治疗学,2012,17(9):1074~1080. [3] 袁琛,黄宁,王静.替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析[J].中国实用医药,2016,11(17):200~201. [4] James SK,Roe MT,Cannon CP,et al.Ticagrelor versus clopidogrel inpatients with acute coronary syndromes intended for non-invasive management:substudy from prospective randomised PLAT elet inhibition and patientOutcomes(PLATO)trial[J].British Medical Journal,2011,342(7812):1403~1403. [5] husteds,jamess,beckerr,et al.Ticagrelor versus clopidogrel in women with acute coronary syndromes-a substudy from the prospectiver and omized platelet inhibition and patient outcomes(plato)trial[J].Circulation Cardiovascular Quality &Outcomes,2012,59(13):e507~e507. [6] 程庆强,高洁,吕中华,等.老年冠心病患者服用替格瑞洛与氯吡格雷出血风险比较[J].中华老年多器官疾病杂志,2016,15(12):881~885.
2020, Vol. 26 
冀公网安备13080202000677号